Posizolid

Identification

Generic Name
Posizolid
DrugBank Accession Number
DB04850
Background

Posizolid (AZD2563) is an oxazolidinone antibiotic. In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though no results were reported).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 465.41
Monoisotopic: 465.134756354
Chemical Formula
C21H21F2N3O7
Synonyms
  • Posizolid
External IDs
  • AZD-2563
  • AZD-5847
  • AZD2563
  • AZD5847

Pharmacology

Indication

For the treatment of gram-positive infections, including multiresistant strains.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

AZD2563 is an oxazolidinone antibiotic. Oxazolidinones inhibit protein synthesis by binding at the P site at the ribosomal 50S subunit. Resistance to other protein synthesis inhibitors does not affect oxazolidinone activity, however rare development of oxazolidinone resistance cases, associated with 23S rRNA alterations during treatment have been reported.

Mechanism of action

AZD2563 selectively inhibits bacterial protein synthesis through binding to sites on the bacterial ribosome and prevents the formation of a functional 70S-initiation complex. Specifically, AZD2563 binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process.

TargetActionsOrganism
A23S ribosomal RNA
antagonist
blocker
Enteric bacteria and other eubacteria
UAmine oxidase [flavin-containing] ANot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Clinical signs of acute toxicity lead to decreased activity, ataxia, vomiting and tremors.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbrisentanThe excretion of Ambrisentan can be decreased when combined with Posizolid.
AsunaprevirThe excretion of Asunaprevir can be decreased when combined with Posizolid.
AtogepantThe serum concentration of Atogepant can be increased when it is combined with Posizolid.
AtorvastatinThe excretion of Atorvastatin can be decreased when combined with Posizolid.
AxitinibThe excretion of Axitinib can be decreased when combined with Posizolid.
Belantamab mafodotinThe excretion of Belantamab mafodotin can be decreased when combined with Posizolid.
BenzylpenicillinThe excretion of Benzylpenicillin can be decreased when combined with Posizolid.
BosentanThe excretion of Bosentan can be decreased when combined with Posizolid.
BrincidofovirThe serum concentration of Brincidofovir can be increased when it is combined with Posizolid.
CaspofunginThe excretion of Caspofungin can be decreased when combined with Posizolid.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as fluorobenzenes. These are compounds containing one or more fluorine atoms attached to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Fluorobenzenes
Alternative Parents
Alkyl aryl ethers / Oxazolidinones / Aryl fluorides / Monosaccharides / Hydropyridines / Tertiary carboxylic acid amides / Carbamate esters / Isoxazoles / Heteroaromatic compounds / Secondary alcohols
show 11 more
Substituents
1,2-diol / Alcohol / Alkyl aryl ether / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Azole / Carbamic acid ester / Carbonic acid derivative
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Mycobacterium tuberculosis
  • Gram-positive Bacteria

Chemical Identifiers

UNII
82V2M8K24R
CAS number
252260-06-3
InChI Key
HBUJYEUPIIJJOS-PBHICJAKSA-N
InChI
InChI=1S/C21H21F2N3O7/c22-15-7-13(26-9-14(33-21(26)30)11-31-18-3-6-32-24-18)8-16(23)19(15)12-1-4-25(5-2-12)20(29)17(28)10-27/h1,3,6-8,14,17,27-28H,2,4-5,9-11H2/t14-,17+/m1/s1
IUPAC Name
(5R)-3-(4-{1-[(2S)-2,3-dihydroxypropanoyl]-1,2,3,6-tetrahydropyridin-4-yl}-3,5-difluorophenyl)-5-[(1,2-oxazol-3-yloxy)methyl]-1,3-oxazolidin-2-one
SMILES
OC[C@H](O)C(=O)N1CCC(=CC1)C1=C(F)C=C(C=C1F)N1C[C@H](COC2=NOC=C2)OC1=O

References

General References
  1. Ednie LM, Jacobs MR, Appelbaum PC: Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J Antimicrob Chemother. 2002 Jul;50(1):101-5. [Article]
  2. Wookey A, Turner PJ, Greenhalgh JM, Eastwood M, Clarke J, Sefton C: AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Clin Microbiol Infect. 2004 Mar;10(3):247-54. [Article]
  3. Howe RA, Wootton M, Noel AR, Bowker KE, Walsh TR, MacGowan AP: Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid. Antimicrob Agents Chemother. 2003 Nov;47(11):3651-2. [Article]
  4. Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK: Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2014;58(1):495-502. doi: 10.1128/AAC.01903-13. Epub 2013 Nov 4. [Article]
  5. Link [Link]
PubChem Compound
213049
PubChem Substance
175426861
ChemSpider
184741
ChEMBL
CHEMBL131854
Wikipedia
Posizolid

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentTuberculosis (TB)1
1CompletedBasic ScienceHealthy Subjects (HS)1
1CompletedTreatmentHealthy Subjects (HS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.71 mg/mLALOGPS
logP1.06ALOGPS
logP0.78ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)12.4ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area125.57 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity109.52 m3·mol-1ChemAxon
Polarizability44.18 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.952
Blood Brain Barrier+0.5501
Caco-2 permeable-0.6145
P-glycoprotein substrateSubstrate0.6905
P-glycoprotein inhibitor IInhibitor0.7726
P-glycoprotein inhibitor IIInhibitor0.5188
Renal organic cation transporterNon-inhibitor0.8467
CYP450 2C9 substrateNon-substrate0.8807
CYP450 2D6 substrateNon-substrate0.8229
CYP450 3A4 substrateSubstrate0.5849
CYP450 1A2 substrateNon-inhibitor0.7627
CYP450 2C9 inhibitorNon-inhibitor0.7437
CYP450 2D6 inhibitorNon-inhibitor0.8141
CYP450 2C19 inhibitorNon-inhibitor0.7377
CYP450 3A4 inhibitorNon-inhibitor0.6273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.812
Ames testNon AMES toxic0.5366
CarcinogenicityNon-carcinogens0.8213
BiodegradationNot ready biodegradable0.9809
Rat acute toxicity2.6132 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.636
hERG inhibition (predictor II)Inhibitor0.8159
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Antagonist
Blocker
In prokaryotes, the 23S rRNA is part of the large subunit (the 50S) that joins with the 30S small subunit to create the functional 70S ribosome. The ribosome is comprised of 3 RNAs: the 23S, the 16S and the 5S ribosomal RNAs. The 23S and the 5S associate with their respective proteins to make up the large subunit of the ribosome, while the 16S RNA associates with its proteins to make up the small subunit.
References
  1. Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Balganesh M, Wright L, Melnick D, Butler SL, Sambandamurthy VK: Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2014;58(1):495-502. doi: 10.1128/AAC.01903-13. Epub 2013 Nov 4. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. AstraZeneca: AZD5847 Oxazolidinone for the treatment of Tuberculosis [File]

Drug created on October 18, 2007 22:53 / Updated on February 21, 2021 18:51